Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.

ABSTRACT:

Introduction

Complex underlying risk functions associated with immuno-oncology treatments have led to exploration of different methods (parametric survival, spline, landmark, and cure-fraction models) to estimate long-term survival outcomes. The objective of this study was to examine differences in estimated short- and long-term survival in previously treated metastatic Merkel cell carcinoma (mMCC) patients receiving avelumab, when using alternative extrapolation approaches.

Methods

Efficacy data from the phase 2 JAVELIN Merkel 200 trial (part A) with at least 12 months of follow-up were analyzed. Standard parametric survival analyses and analyses of overall survival (OS) as a function of surrogate outcomes comprised of response (landmark analyses) and progression-free survi

SUBMITTER: Lanitis T 

PROVIDER: S-EPMC6822847 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature